To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Researchers at the Barbara Ann Karmanos Cancer Institute have published a review article in the American Journal of Clinical Oncology on the standard of care for hormone receptor-positive, early-stage breast cancer. The study, “A Review of Endocrine Therapy in Early-Stage Breast Cancer: The Journey from Crudeness to Precision,” discusses how treatment models for hormone-positive breast cancer need to be more personalized. “This article summarizes the milestone trials of a new era in treating hormone-pos...
HealthyWomen Karmanos patient Barbara Daley shared her metastatic breast cancer story with HealthyWomen. Her medical oncologist, Jailan Elayoubi, M.D. , member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams at Karmanos, further discussed new treatments available to metastatic patients. Read the article here .
OncLive Four leading medical oncologists, all members of the Breast Cancer Multidisciplinary Team (MDT) at Barbara Ann Karmanos Cancer Institute, talk about treatments and clinical trials for breast cancer. Hadeel Assad, M.D. , also member of the Phase I Clinical-Pharmacology MDT, discussed how CDK4/6 inhibitors have been implemented into practice, as well as updates on HER2-positive breast cancer and triple-negative breast cancer clinical trials. Lawrence Flaherty, M.D. , discus...